, Tracking Stock Market Picks
Enter Symbol:

up 6.76 %

LEXICON PHARMACEUTCL (LXRX) rated Underperform with price target $1.50 by BofA/Merrill

Posted on: Friday,  Dec 6, 2013  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform LEXICON PHARMACEUTCL (NASDAQ: LXRX) on 12/06/2013, when the stock price was $12.95. Since
then, LEXICON PHARMACEUTCL has lost 6.33% as of 01/04/2016's recent price of $12.13.
If you would have followed this BofA/Merrill's recommendation on LXRX, you would have gained 6.76% of your investment in 759 days.

Lexicon Pharmaceuticals, Inc. (Lexicon), is a biopharmaceutical company focused on discovering and developing treatments for human disease. The Company uses its proprietary gene knockout technology to identify and develop new drugs. In its Genome5000 program, Lexicon is utilizing its knowledge of the function of nearly 5,000 genes to identify a portfolio of drug targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a diverse pipeline of drug targets behind its clinical programs with many compounds and antibodies in preclinical research. Lexicon is conducting clinical trials for four drug candidates, with its most advanced program in Phase II clinical trials.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/6/2013 8:25 AM Sell
12.95 10.50
as of 12/13/2013
1 Week up  4.86 %
1 Month up  4.86 %
3 Months   
1 YTD up  4.86 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy